# CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

> **NCT01766219** · PHASE1,PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 17 (actual)

## Conditions studied

- Adult Primary Cholangiocellular Carcinoma
- Advanced Adult Primary Liver Cancer
- Cholangiocarcinoma of the Extrahepatic Bile Duct
- Cholangiocarcinoma of the Gallbladder
- Localized Unresectable Adult Primary Liver Cancer
- Metastatic Extrahepatic Bile Duct Cancer
- Recurrent Adult Primary Liver Cancer
- Recurrent Extrahepatic Bile Duct Cancer
- Unresectable Extrahepatic Bile Duct Cancer

## Interventions

- **DRUG:** 6,8-bis(benzylthio)octanoic acid

## Key facts

- **NCT ID:** NCT01766219
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2018-04
- **Final completion:** 2018-05-18
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01766219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01766219, "CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01766219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*